{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.464.1003.1151","meta":{"versionId":"6","lastUpdated":"2021-11-02T01:01:44.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1151","version":"20211102","name":"Substance Use Disorder Long Acting Medication Administration","status":"active","date":"2021-11-02T01:01:44-04:00","publisher":"NCQA PHEMUR","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2022","concept":[{"code":"G2069","display":"Medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)"},{"code":"G2070","display":"Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)"},{"code":"G2072","display":"Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)"}]}]}}